Drug
Suvemcitug clinical trials
Also written Sevacizumab and BD0801.
Keep track of what changes. Save the suvemcitug studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Other names
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2021 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 2
Jiangsu Simcere Pharmaceutical Co., Ltd. (6) · Fudan University (1) · Peking University Third Hospital (1)
Often tested with
Tested in the same studies.
Modified FOLFOX6 Regimen (1) · Enlonstobart (1) · Mirvetuximab soravtansine (1) · Trifluridine (1) · Tipiracil (1)
Studies
Open first, then newest update. How each study uses suvemcitug is read from its arms, and is right about nine times in ten.
Testing it · 8
- Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal CancerNot yet recruitingPhase 2Fudan UniversityNCT07810114Written as Suvemcitug
- Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingPhase 2Peking University Third HospitalNCT07741630Written as Suvemcitug
- A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal CancerRecruitingPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT07361003Written as Suvemcitug injection, trifluridine/tipiracil tablets
- A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian CancerCompletedPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT04908787Written as BD0801
- A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid TumorsTerminatedPhase 2Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05148195Written as BD0801
- A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.Status unknownPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT03763123Written as Sevacizumab
- A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal CancerStatus unknownPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT02453464Written as Sevacizumab
- A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid TumorsStatus unknownPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT01847118Written as Sevacizumab
Codes
What other systems call suvemcitug · ClinicalTrials.gg INT017995
- UNII (FDA) T7Y5VC4ERJSUVEMCITUGOne source FDA
- NCI Thesaurus C122403SuvemcitugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | T7Y5VC4ERJ | SUVEMCITUG | One source FDA |
| NCI Thesaurus | C122403 | Suvemcitug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.